Established in 1992, the 340B Drug Pricing Program has many nuances and applications to different situations. Fundamentally, it requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible safety-net hospitals and clinics, requires pharmaceutical manufacturers to provide up-front discounts and pharmaceutical manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices. The conditions of participation and compliance are not simple.
The goal of this webinar is to explain key facets of the 340B Program and delve into recent opinions from the U.S. Courts of Appeals for the Ninth Circuit and the Fourth Circuit.
This program examines listening as an active, strategic trial advocacy skill rather than a passive c...
Disasters, whether natural or manmade, happen. Disasters can impact the practice of law and, among o...
This program reframes domestic violence through the lens of “intimate terrorism,” equipp...
Resilience in the Workplace, delves into the critical importance of resilience in navigating the cha...
This course provides a roadmap for ethical AI integration in high-volume practices through real-worl...
In this second segment we will continue with our journey into the multiple elements of high-level ne...
This program provides a detailed examination of the Black Market Peso Exchange (BMPE), one of the mo...
Aligning Your Legal Career with Your Values, explores the profound impact of values alignment on ind...
Large World Models (LWMs)— the next generation of AI systems capable of generating...
In 2016, the term “materiality” as it relates to the False Claims Act made a splash in t...